[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Ruiz-Hernández G, Delgado-Bolton RC, Rubio-Pérez MJ, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras-Delgado JL: [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):326-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET].
  • OBJECTIVE: To present the case report of a patient with undifferentiated and diffuse signet-ring cell gastric carcinoma in which FDG-PET evidenced recurrent disease.
  • The patient was treated with chemotherapy and radiotherapy, reaching a complete response.
  • CONCLUSIONS: In this case report we stress the importance of early recurrence by FDG-PET in a non-intestinal gastric carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194466.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Ferry JA: Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist; 2006 Apr;11(4):375-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
  • Burkitt's lymphoma is a highly aggressive lymphoma identified and described in the last century by Denis Burkitt in Africa, in areas endemic for malaria.
  • Since its initial designation as Burkitt's lymphoma, this type of lymphoma and lymphomas closely resembling it have received a variety of names in different classifications of lymphomas and leukemias: undifferentiated lymphoma, Burkitt's and non-Burkitt's type in the modified Rappaport Classification, malignant lymphoma, small non-cleaved cell, Burkitt's type in the Working Formulation, Burkitt's lymphoma and high-grade B-cell lymphoma, Burkitt-like in the REAL Classification, and acute lymphoblastic leukemia, L3 type in the FAB Classification.
  • With the publication of the WHO Classification of Haematopoietic and Lymphoid Tumors, the nomenclature of this lymphoma has come full circle, and it is once again known simply as Burkitt's lymphoma.
  • In recent years, efforts have focused on improving therapy for this rapidly proliferating neoplasm while minimizing, to the extent possible, treatment-associated toxicity.
  • These efforts have led to the development of high-intensity, short-duration combination chemotherapy that has proven extremely effective for a high proportion of Burkitt's lymphoma patients.
  • The differential diagnosis of Burkitt's lymphoma is broad, and precise diagnosis based on histologic, immunophenotypic, and genetic features remains the critical first step in planning appropriate therapy.
  • [MeSH-major] Burkitt Lymphoma / pathology


3. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A: Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol; 2008 Jun;21(6):708-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.
  • Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification for cutaneous lymphomas, is not well characterized.
  • Most cases showed normal T-cell antigen expression; diminished/absent expression of CD7 was seen in three cases and CD2 expression was absent in one case.
  • The majority resolved without relapse, one without treatment, four with excision, and four with radiation therapy.
  • One patient developed local recurrence.
  • The patient with multiple lesions had disease progression despite chemotherapy and stem cell transplant.
  • These cases highlight the polymorphous histology and prominent reactive B-cell component of this entity.
  • The differential diagnosis includes reactive lymphoid hyperplasia, mycosis fungoides and cutaneous B-cell lymphomas.
  • In patients with isolated cutaneous lesions, the indolent behavior of this rare T-cell neoplasm should be recognized to avoid unnecessary treatment.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. History, 17th Century. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Male. Middle Aged. Mycosis Fungoides / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311111.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Jayanthi V, Randhir J, Rajesh N: Problems in diagnosing lymphoma of the pancreas with computed tomography. A case report. J Gastrointestin Liver Dis; 2007 Mar;16(1):101-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Problems in diagnosing lymphoma of the pancreas with computed tomography. A case report.
  • Primary lymphoma of the pancreas is a rare form of extranodal lymphoma accounting for less than 0.5% of pancreatic tumors.
  • A 73 year old male presented with recurrent pancreatic type abdominal pain with significant weight loss over 1 year.
  • Contrast enhanced CT showed an ill defined poorly marginated non enhancing hypodense mass lesion involving the body of the pancreas.
  • It was negative for CD3 and CD 20 indicating an undifferentiated lymphoma.
  • Patient received two sessions of chemotherapy and was followed-up.
  • [MeSH-major] Adenocarcinoma / radiography. Lymphoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410296.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


5. Quéreux G, Renaut JJ, Peuvrel L, Knol AC, Brocard A, Dréno B: Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol; 2010 Nov;90(6):616-20
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
  • Psoriasis is thought to be associated with an increased risk of lymphoma.
  • We report here the first case of an aggressive primary cutaneous pleomorphic T-cell lymphoma in a patient with psoriasis.
  • A biopsy confirmed a stage IVa primary cutaneous pleomorphic T-cell lymphoma.
  • Despite treatment with pegylated liposomal doxorubicin, the disease progressed and the patient died 5 months later.
  • This case of pleomorphic T-cell lymphoma was remarkable in both its extremely rapid onset and the aggressive nature of the disease.
  • The onset of this disease in a patient with psoriasis who had been previously treated with immunosuppressive drugs and a tumour necrosis factor (TNF)-α blocker is of major interest.
  • Only eight cases of cutaneous lymphomas associated with treatment with TNF-α blockers have been published previously.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Lymphoma, T-Cell, Cutaneous / chemically induced. Psoriasis / drug therapy. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Biopsy. Cyclosporine / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etanercept. Fatal Outcome. Humans. Immunoglobulin G / adverse effects. Leg. Male. Methotrexate / adverse effects. Neoplasm Invasiveness. Neoplasm Staging. Polyethylene Glycols / therapeutic use. Receptors, Tumor Necrosis Factor. Treatment Failure

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057746.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; OP401G7OJC / Etanercept; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Copur MS, Deshpande A, Mleczko K, Norvell M, Hrnicek GJ, Woodward S, Frankforter S, Mandolfo N, Fu K, Chan WC: Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Croat Med J; 2005 Jun;46(3):458-62
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
  • Primary cutaneous T- and B-cell lymphomas are a heterogeneous group of diseases with varied clinical presentations and prognosis.
  • Cutaneous B-cell and T-cell lymphomas are seldom found together in the same patient.
  • Here we report a rare case of mycosis fungoides variant of a cutaneous T-cell lymphoma (CTCL) which later developed Epstein-Barr virus (EBV) associated cutaneous B-cell lymphoproliferative disorder.
  • Histopathology and immunophenotyping of her tumor from the right breast nodule revealed a T-cell lymphoma consistent with mycosis fungoides.
  • After progression of her mycosis fungoides with worsening diffuse skin lesions on this regimen, her treatments were changed to oral bexarotene with an initial partial response followed by stable disease.
  • Three years from her initial presentation, she developed ulcerated cauliflower-like nodules on her forehead.
  • Biopsy of these lesions revealed EBV-positive large- and medium-sized pleomorphic B-cells consistent with EBV-driven B-cell lymphoproliferative disorder.
  • Skin lesions gradually diminished and totally disappeared after four weeks of topical acyclovir treatment.
  • Bexarotene treatment was continued for another year until the mycosis fungoides progressed and became wide spread causing her death four and a half years after the initial diagnosis.
  • The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage in the same patient and the complete clinical response of EBV-related B-cell cutaneous component to topical acyclovir makes this rare case particularly interesting.
  • [MeSH-major] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861527.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


7. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C: Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J; 2004 Mar;167(2):158-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
  • The aim of this study was to determine the response of different morphological subtypes of canine lymphoma to a standardized therapeutic protocol.
  • Diagnosis of lymphoma was based on cytohistological analysis and immunophenotyping with antibodies against CD3 and CD79a of an enlarged lymph node or an extranodal mass.
  • Fifty-seven cases were classified according to the updated Kiel classification adapted to the canine species, into 24 B-cell lymphomas (20 centroblastic polymorphic and four Burkitt-type subtypes), and 33 T-cell lymphomas (10 pleomorphic mixed, 10 lymphoblastic, eight unclassifiable high grade plasmacytoid, and five small clear-cell subtypes).
  • First remission duration and overall survival time were evaluated.
  • Although the T-cell phenotype was associated, on the whole, with a poor prognosis, as previously reported in veterinary and human medicine, the study showed significant prognostic differences between the B- and the T-cell subtypes of canine lymphoma and suggests that clinico-morphological characterization of the disease is justified in dogs, as in humans.
  • [MeSH-major] Dog Diseases / classification. Dog Diseases / epidemiology. Lymphoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dogs. Female. France / epidemiology. Immunophenotyping / veterinary. Male. Prognosis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet J. 2004 Mar;167(2):125-6 [14975385.001]
  • (PMID = 14975390.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Wawrzycki B, Chodorowska G, Pietrzak A, Jazienicka I, Skomra D, Kowal M, Dybiec E, Hercogova J: Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide. Dermatol Ther; 2010 Nov-Dec;23(6):676-81
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide.
  • Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas.
  • Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification.
  • It still awaits development of more precise diagnostic criteria and optimal therapy.
  • We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide.
  • It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. CD4-Positive T-Lymphocytes / drug effects. Cyclophosphamide / therapeutic use. Leukemia, Myelomonocytic, Chronic / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Myelodysplastic Syndromes / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Immunohistochemistry. Skin / immunology. Skin / pathology. Treatment Outcome


9. Ranganathan S, Webber S, Ahuja S, Jaffe R: Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol; 2004 Jul-Aug;7(4):348-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
  • Most post-transplant lymphoproliferative disorders (PTLD) are polymorphic in appearance; some are monomorphic and can resemble conventional malignant lymphomas.
  • PTLD that resembles Hodgkin lymphoma has been reported infrequently.
  • We herein report seven cases of PTLD that have large numbers of Reed-Sternberg-like (RS-like) cells and highlight differences in the phenotype of these cases that may distinguish Hodgkin-like PTLD (HL-PTLD) from true Hodgkin lymphoma/disease (HD).
  • The large cells of HL-PTLD are pleomorphic B cells that react strongly for CD20 and/or CD79a, express CD30, but are usually negative for CD15 and have few mitoses.
  • A single case of true Hodgkin lymphoma has highly atypical RS-like cells that contain numerous mitoses, does not have CD20 or CD79a reactivity, has CD15 and CD30 staining, and the EBER-1 probe is confined to the large cells only.
  • All patients were managed by withdrawal of immunosuppression and variably treated with either antiviral or anti-CD20 monoclonal antibody, or with chemotherapy.
  • [MeSH-major] Hodgkin Disease / etiology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Society for Pediatric Pathology
  • (PMID = 14564542.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


10. Murakami T, Fukasawa T, Fukayama M, Usui K, Ohtsuki M, Nakagawa H: Gene expression profile in a case of primary cutaneous CD30-negative large T-cell lymphoma with a blastic phenotype. Clin Exp Dermatol; 2001 Mar;26(2):201-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile in a case of primary cutaneous CD30-negative large T-cell lymphoma with a blastic phenotype.
  • Histological examination showed diffuse and dense infiltrates located in the dermis and subcutis, composed of large pleomorphic T lymphocytes.
  • Immunohistochemically, neoplastic cells were positive for blastic T-cell markers, but negative for CD30 (Ki-1) antigen.
  • Based on the clinicopathological findings, a diagnosis of primary cutaneous large T-cell lymphoma was made.
  • Despite systemic chemotherapy, the patient died 7 months after diagnosis.
  • Comprehensive gene expression patterning in additional cases may provide useful information regarding the biological and clinical behaviour of aggressive cutaneous lymphomas such as CD30-negative large T-cell lymphoma.
  • [MeSH-major] Cytokines / genetics. Intracellular Signaling Peptides and Proteins. Lymphoma, T-Cell, Cutaneous / genetics. Receptors, Cytokine / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Antigens, CD30. CASP8 and FADD-Like Apoptosis Regulating Protein. Carrier Proteins / genetics. Chemokine CCL2 / genetics. Chemokine CCL8. Chemokine CXCL10 / genetics. Female. Gene Expression. Humans. Monocyte Chemoattractant Proteins / genetics. Proliferating Cell Nuclear Antigen / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298116.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CCL8 protein, human; 0 / CFLAR protein, human; 0 / Carrier Proteins; 0 / Chemokine CCL2; 0 / Chemokine CCL8; 0 / Chemokine CXCL10; 0 / Cytokines; 0 / Intracellular Signaling Peptides and Proteins; 0 / Monocyte Chemoattractant Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, Cytokine
  •  go-up   go-down


11. Lee EJ, Kim TW, Heo JW, Yu HG, Chung H: Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report. Eur J Ophthalmol; 2010 Jan-Feb;20(1):215-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell lymphoma of nasal type with intraocular involvement: case report.
  • PURPOSE: To report an unusual presentation of disseminated, intraocular, extranodal natural killer/T-cell lymphoma, nasal type (NK/T-cell lymphoma), originating from nasal NK/T-cell lymphoma.
  • RESULTS: A 63-year-old woman who had been treated with systemic chemotherapy and radiotherapy for NK/T-cell lymphoma in the nasal cavity presented with vitreous haze of the right eye.
  • Despite anti-inflammatory therapy, the right eye showed poor clinical response and received diagnostic vitrectomy.
  • The vitreous specimen contained many large, pleomorphic lymphoma cells.
  • A diagnosis of T-cell lymphoma in the vitreous was made; the tumor likely originated from nasal NK/T-cell lymphoma.
  • The patient was treated with intrathecal chemotherapy and intravitreal methotrexate injection.
  • CONCLUSIONS: Vitreous infiltration without uveoretinal involvement can be an unusual manifestation of intraocular NK/T-cell lymphoma.
  • Clinician awareness of possible ocular involvement may assist in the diagnosis of disseminated NK/T-cell lymphoma.
  • [MeSH-major] Eye Neoplasms / pathology. Killer Cells, Natural. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology. Vitreous Body / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Injections, Spinal. Middle Aged. Neoplasm Invasiveness. Vitrectomy

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882515.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Laver JH, Mahmoud H, Pick TE, Hutchison RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2002 Jan;43(1):105-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • PATIENTS AND METHODS: One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve remission.
  • CONCLUSION: The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prednisone / administration & dosage. Prospective Studies. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA05587; United States / NCI NIH HHS / CA / CA11233; United States / NCI NIH HHS / CA / CA15089; United States / NCI NIH HHS / CA / CA20549; United States / NCI NIH HHS / CA / CA25408; United States / NCI NIH HHS / CA / CA28383; United States / NCI NIH HHS / CA / CA28476; United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30696; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA35587; United States / NCI NIH HHS / CA / CA69177; United States / NCI NIH HHS / CA / CA69428
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ACOP protocol 2
  •  go-up   go-down


13. Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ, Pediatric Oncology Group: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2001 Jul;42(3):399-405
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve.
  • In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Child. Continental Population Groups. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Neoplasm Metastasis. Prednisolone / administration & dosage. Prednisone / administration & dosage. Remission Induction. Time Factors. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699405.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; VAP-cyclo protocol; VPD protocol
  •  go-up   go-down


14. Re M, Di Massimo U, Romeo R, Mallardi V: Burkitt-like lymphoma of the sphenoid sinus: case report. Acta Otorhinolaryngol Ital; 2004 Feb;24(1):30-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-like lymphoma of the sphenoid sinus: case report.
  • Burkitt's lymphoma is a malignant endemic neoplasia with a mandibular localization, described for the first time in 1958, in African children.
  • The World Health Organization classification recognises several variants of Burkitt's lymphoma; all are highly malignant B cell lymphomas.
  • Besides Burkitt's sporadic, endemic lymphoma and Burkitt's lymphoma associated with AIDS, the World Health Organization classification includes an "atypical or pleomorphic" variant of Burkitt's lymphoma.
  • This subtype includes those cases diagnosed as "Burkitt-like" lymphoma in the REAL (Revised European-American Classification of Lymphoid Neoplasm).
  • The therapeutic protocol is similar to that used for classic Burkitt's lymphoma, with chemotherapy being standard treatment.
  • The case is described of a sinus-nasal "Burkitt-like lymphoma", originating within sphenoid sinus.
  • The extremely rare localisation of this histological variant of Burkitt's lymphoma is stressed as well as the extremely aggressive nature of the neoplasm.
  • [MeSH-major] Burkitt Lymphoma / classification. Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus / radiography
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15270431.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Hathaway T, Subtil A, Kuo P, Foss F: Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma; 2007 Sep;7(8):541-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma.
  • Subcutaneous panniculitis-like lymphomas (SPTCLs) are a heterogeneous group of diseases characterized by pleomorphic lymphocytes infiltrating the subcutis in a lobular panniculitis-like pattern.
  • Characterization of SPTCL based on T-cell phenotype has prognostic significance in that most patients with the alpha/beta T-cell phenotype of SPTCL demonstrate clinically indolent behavior, whereas those with gamma/delta variant typically manifest more aggressive disease.
  • In the past, traditional therapies have included single-agent or systemic multi-agent chemotherapy with or without radiation therapy, immunosuppressive therapies, or, in refractory patients, bone marrow transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Panniculitis / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Humans. Male. Middle Aged. Recombinant Fusion Proteins / therapeutic use. Tomography, Emission-Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021473.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


16. Héliot-Hosten I, Versapuech J, Vergier B, Taieb A, Delaunay M: [Cutaneous CD8+ squamous T-cell bullous lymphoma]. Ann Dermatol Venereol; 2005 Apr;132(4):359-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous CD8+ squamous T-cell bullous lymphoma].
  • [Transliterated title] Lymphome cutané épidermotrope CD8 + bulleux.
  • INTRODUCTION: Bullous forms of cutaneous T-cell lymphomas are rare.
  • A new group of cutaneous T-cell lymphomas has recently been identified as a distinct clinicopathological and immunophenotype entity.
  • These cutaneous T-cell lymphomas express a CD8+ phenotype, rarely expressed in other cutaneous T-cell lymphomas.
  • CASE REPORT: We describe a cutaneous CD8+ squamous T-cell lymphoma with polymorphic clinical features, strongly epidermotropic lymphoid infiltrate and spongiosis, classical for this type of lymphoma.
  • DISCUSSION: Bullous lesions in cutaneous T-cell lymphoma should evoke the possibility of a cutaneous CD8+ T-cell lymphoma, once other bullous diseases have been excluded.
  • Spongiosis, rare in other types of T-cell lymphoma, and strongly epidermotropic pleomorphic lymphoid infiltrate are classical histological features.
  • Treatment is difficult and classical chemotherapy often fails.
  • [MeSH-major] CD8-Positive T-Lymphocytes. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886565.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Guizzardi M, Hendrickx IA, Mancini LL, Monti M: Cytotoxic gamma/delta subcutaneous panniculitis-like T-cell lymphoma: report of a case with pulmonary involvement unresponsive to therapy. J Eur Acad Dermatol Venereol; 2003 Mar;17(2):219-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic gamma/delta subcutaneous panniculitis-like T-cell lymphoma: report of a case with pulmonary involvement unresponsive to therapy.
  • Peripheral subcutaneous panniculitis-like T-cell lymphoma (PSPTCL) is a rare form of cutaneous lymphoma recently proposed as a distinct clinicopathological entity.
  • Finding of TIA-1+ and perforin + cytolytic granules in atypical pleomorphic lymphocytes suggests PSPTCL origin from granular cells of T-cell or natural killer cell phenotype.
  • Cells have a CD3+ CD4+ CD8- or CD3+ CD4- CD8+ T-cell phenotype.
  • Moreover, these lymphomas can express natural killer cell associated antigens, such as CD56, especially in gamma/delta variants.
  • The prognosis of most PSPTCL is poor even when treated with aggressive chemotherapy.
  • This paper reports a case of PCTCL in a young woman with T-cytotoxic differentiation, with rapid progression unresponsive to several treatments.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Panniculitis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Fatal Outcome. Female. Humans. Killer Cells, Natural / pathology. Prednisone. Vincristine


18. Parker JR, López-Terrada D, Gresik MV, Vogel H, Baumgartner JE, Finegold MJ: Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma. Pediatr Dev Pathol; 2001 Jul-Aug;4(4):397-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil-rich anaplastic large cell lymphoma of the skull presenting after head trauma.
  • The presentation of anaplastic large cell lymphoma in bone is uncommon.
  • We report a case of anaplastic large cell lymphoma of the skull that was diagnosed after head trauma.
  • The tumor cells had large, pleomorphic nuclei; these cells stained positively with antibodies to Ki-1 (CD 30), ALK-1, and EMA.
  • Fluorescence in situ hybridization (FISH) showed rearrangement of the ALK gene, which usually results from the t(2;5) translocation, present in most anaplastic large cell lymphomas.
  • The patient has tolerated chemotherapy and is free of disease 12 months later.
  • [MeSH-major] Antigens, CD30. Craniocerebral Trauma. Lymphoma, Large-Cell, Anaplastic / pathology. Neutrophils / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Activin Receptors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Nucleus / chemistry. Cell Nucleus / genetics. Cell Nucleus / pathology. Child. DNA, Neoplasm / analysis. E2F6 Transcription Factor. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Protein-Serine-Threonine Kinases / analysis. Protein-Serine-Threonine Kinases / genetics. Repressor Proteins / analysis. Transcription Factors / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Head Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441342.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / DNA, Neoplasm; 0 / E2F6 Transcription Factor; 0 / E2F6 protein, human; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors
  •  go-up   go-down


20. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • We reported eight cases of stage IV small cell neuroendocrine carcinoma of the head and neck, all in men with a mean onset age of 62 years (range: 45 to 80 years).
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


21. Chuman H: [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2003 May;30(5):626-33
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma].
  • The cell origin, molecular mechanism of pleomophism and mechanism of pleomorphic change in a cell undergoing malignant change have not been elucidated.
  • MFH-like histological changes are observed in many bone and cartilage sarcomas, and some renal cell carcinomas and malignant lymphomas.
  • The sensitivity of MFH to radiotherapy and chemotherapy is insufficient, and evidence is lacking for adjuvant treatment.
  • Rescue following initial treatment failure is extremely difficult.
  • For treatment of bone and soft tissue sarcoma, a correct diagnosis and initial treatment are extremely important.
  • Many cases need to be accumulated in joint clinical studies across fields according to organ and specialty, and effective treatment method developed.
  • We need to advance the standardization of treatment for MFH, and eliminate wrong initial treatment through the active provision of information.
  • [MeSH-major] Bone Neoplasms. Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Prognosis. Radiotherapy, Adjuvant. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / therapy. Survival Rate

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y: Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci; 2009 Jan;100(1):54-61
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern.
  • We examined histological and immunohistochemical changes in 59 patients with B-NHL after rituximab therapy.
  • Pre-rituximab specimens comprised 34 follicular lymphomas (FL), 11 diffuse large B-cell lymphomas (DLBCL), 10 mantle cell lymphomas, two marginal zone B-cell lymphomas (MZBCL), and two chronic lymphocytic leukemias (CLL).
  • CD20 expression in lymphoma cells was evaluated by immunohistochemistry or flow cytometry.
  • Post-rituximab materials were taken a median of 6 months (4 days to 59 months) after rituximab therapy.
  • Sixteen cases (27%) showed loss of CD20 expression with four histological patterns: pattern 1, no remarkable histological change (FL, 5; DLBCL, 3; and CLL, 2); pattern 2, proliferation of plasmacytoid cells (FL, 2; DLBCL, 1; and MZBCL, 1); pattern 3, transformation to classical Hodgkin's lymphoma (FL, 1); and pattern 4, transformation to anaplastic large cell lymphoma-like undifferentiated lymphoma (FL, 1).
  • Loss of CD20 was unrelated to the interval of biopsies, treatment regimen, clinical response, and frequency of rituximab administration.
  • Loss of CD20 within 1 month of rituximab therapy (3/14, 21%) and regain of CD20 (2/7, 29%) were not frequent.
  • In conclusion, B-NHL showed various histological and immunophenotypic changes after rituximab therapy, including not only CD20 loss but also proliferation of plasmacytoid cells or transformation to special subtypes of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038008.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Ruco LP, Di Napoli A, Pilozzi E, Talerico C, Uccella I, Giancola ML, Alba L, Antinori A: Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients? AIDS Res Hum Retroviruses; 2004 Feb;20(2):129-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients?
  • Recently, a 15-fold increased risk of T cell lymphomas has been estimated in HIV-infected populations.
  • This increase has been observed for all T cell lymphoma subtypes.
  • In the present report we describe clinical and pathological features of three consecutive cases of peripheral T cell lymphoma (PTCL) with cytotoxic phenotype in HIV-positive patients that came to our attention in May-September 2002.
  • The risk factor for each patient was heterosexual, injecting drug user, and homosexual, respectively.
  • CD4 cell counts were low (79-81 cells/mm3).
  • Two patients were naive for antiretroviral therapy.
  • At histological examination, all the involved tissues were effaced by a neoplastic proliferation of CD3+/CD8+ medium to large pleomorphic cells containing TIA-1+ cytotoxic granules and a few granzyme B+ granules.
  • They were negative for the B cell antigens CD20 and CD79a, for CD30 and for CD56.
  • Clonal T cell receptor-g (TCR-g) rearrangements were demonstrated in the three cases.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15018699.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Kuo TT, Shih LY, Tsang NM: Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol; 2004 Oct;12(4):375-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities.
  • Nasal NK/T cell lymphoma is a distinctive type of extranodal lymphoma with an unique immunophenotype and a strong association with Epstein-Barr virus (EBV).
  • It is one of the common extranodal lymphomas in Taiwan.
  • We studied 22 cases of nasal NK/T cell lymphoma to characterize their clinicopathologic features and to explore the possible differences between histologic subtypes and their clinical behavior as well as the prevalence of 30-base pair (bp) deleted latent membrane protein-1 (LMP-1) gene of the EBV.
  • They consisted of 5 cases of small cell type (SC), 6 cases of medium-sized cell type (MC), 6 cases of large cell type (LC), and 5 cases of pleomorphic cell type (PC).
  • The median ages of the LC type and PC type were older than the other 2 types.
  • All but 1 case had stage IE disease at the time of diagnosis.
  • Five cases developed extranasal involvement and skin was the most common site.
  • The majority of patients received local radiotherapy and chemotherapy.
  • Local irradiation was more effective than chemotherapy alone.
  • Nine cases of various cell types (41%) were also CD30+.
  • Among the 4 histologic subtypes, the SC type differed from the other types by the absence of angiodestruction and necrosis, although angioinvasive growth was seen in 2 of them.
  • Pseudoepitheliomatous hyperplasia was seen in only 3 cases of the SC type, and all 5 cases of the SC type were CD30-.
  • A high prevalence rate of 86% (19/22) of the 30-base pair (bp) deleted LMP-1 gene was found, but 81.5% (22/27) of the EBV-positive control reactive lymphoid tissues also had the 30-bp deleted LMP-1 gene.
  • Therefore, the high prevalence of the 30-bp deleted LMP-1 gene found in NK/T cell lymphoma could be due to the high prevalence of the deleted variant in this geographic region.
  • However, it remains possible that the high prevalence of the deleted LMP-1 gene contributed to the increased incidence of EBV-associated nasal NK/T cell lymphoma in Taiwan.
  • [MeSH-major] Herpesvirus 4, Human. Killer Cells, Natural / pathology. Lymphoma, T-Cell, Peripheral / pathology. Nose Neoplasms / pathology. Viral Matrix Proteins / genetics

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494863.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


25. Héliot I, Beylot-Barry M, Vergier B, Doutre MS, Beylot C: [Cutaneous T-cell lymphoma bullosa: 2 cases]. Ann Dermatol Venereol; 2003 Jun-Jul;130(6-7):639-42
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous T-cell lymphoma bullosa: 2 cases].
  • [Transliterated title] Lymphome T bulleux: 2 cas.
  • INTRODUCTION: Since the first case described by Kaposi in 1887, bullous forms of cutaneous T-cell lymphomas are extremely.
  • CASE-REPORT: We describe an unusual case of mycosis fungoides bullosa with palmoplantar dyshidrosis-like eruption and, to our knowledge, the first case of pleomorphic cutaneous T-cell lymphoma bullosa.
  • DISCUSSION: Cutaneous T-cell lymphoma bullosa can be very misleading, particularly when the bullous lesions are inaugural.
  • Differential diagnosis have to be excluded (autoimmune blistering diseases or contact dermatitis during topical treatment of lymphoma or bacterial or viral cutaneous infections) by biopsy, direct immunofluorescence and bacteriological examinations.
  • In these cutaneous lymphoma bullosa, the blisters appear to de due to excessive epidermotropism and/or toxicity of the tumoral infiltrate.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous. Skin Neoplasms
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Diagnosis, Differential. Fluorescent Antibody Technique, Direct. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Mycosis Fungoides / diagnosis. Mycosis Fungoides / drug therapy. Mycosis Fungoides / pathology. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13679703.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement